Press Releases

To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.

Initiator Pharma reports the final analysis of positive efficacy data from the IPTN2021 program Phase I study

Initiator Pharma A/S, a clinical-stage pharma company, announced today that the final dataset and study- report analysis have been obtained in the IPTN2021 program. The IPTN2021 program is a clinical Phase I study in healthy subjects dosed with the drug IP2015 and challenged with a pain-inducing ingredient (capsaicin). The final analysis confirms the statistically significant effects on pain measures that were observed in the analysis of the first data read-out from the study presented in May 2022.

Prolongation of the share buyback program

The Board of Directors of Initiator Pharma A/S (“Initiator” or the “Company”) has today resolved to prolong the duration of the share buyback until 26 July 2022